At least 23 biotechs and pharmas are slated to report earnings this week. Emergent BioSolutions Inc. (NYSE:EBS) and Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) are expected to report EPS growth of 70% or more. Analysts expect revenues for anthrax vaccine manufacturer Emergent to grow 23% to $71.9 million, while revenues for specialty pharma Valeant are expected to be up 45% to $873.5 million, helped by recent acquisitions like iNova Pharmaceuticals Pty. Ltd. On the other hand, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is anticipated to report